We report and review the clinical effectiveness of aromatase inhibitors in a patient with refractory, recurrent and infiltrating endometriosis. We demonstrate excellent clinical, radiological and endoscopic responses after failure of multiple other modalities. Our case and the literature show that single-agent letrozole is capable to treat deep infiltrative endometriosis involving the rectum and the urinary tract. The use of aromatase inhibitor treatment of endometriosis in postmenopausal women makes sense, is safe and is well tolerated. Difficult cases of deep infiltrative endometriosis might require use of combined surgical and medical treatment modalities. Multidisciplinary involvement of the gynecologist, bowel surgeon, urologist and invasive radiologist might be needed. Aromatase inhibitors should be considered to be an integral part of the armamentarium in the management of women with endometriosis, especially in refractory cases that have failed conventional therapeutic modalities.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Rotenberg, O., Kuo, D. Y. S., & Goldberg, G. L. (2022). Use of aromatase inhibitors in menopausal deep endometriosis: a case report and literature review. Climacteric. Taylor and Francis Ltd. https://doi.org/10.1080/13697137.2021.1990259